Asset profile
Cabozantinib
Small molecule
Approvedregulatory verdict
Evidence outlook
Approved: Clear Cell Renal Cell Carcinoma, Hepatocellular Carcinoma
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
Also in development:Non-Small Cell Lung Cancer · Phase 3
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
68 competitors in this universe: 0 direct rivals (same mechanism and indication), 0 same-class, 68 same-indication.
Unlock with Research ↗
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| Cabozantinib: this drug | Approved | Small molecule | Multi-kinase inhibitor (VEGFR/PDGFR/KIT) | ||
| Afatinib (Gilotrif) | Approved | Small molecule | EGFR/HER1, HER2, HER4 | ||
| Alectinib (Alecensa) | Approved | Small molecule | ALK | ||
| Alymsys (bevacizumab-Maly) | Approved | Monoclonal antibody | VEGF-A | ||
| Amivantamab | Approved | Multispecific antibody | EGFR x c-MET | ||
| Atezolizumab | Approved | Monoclonal antibody | PD-L1 | ||
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | ||
| BAY2927088 (Hyrnuo) | Approved | Small molecule | HER2 (ERBB2) exon 20 insertions and point mutations; also mutant-selective EGFR | ||
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | ||
| Bevacizumab-Awwb (MVASI) | Approved | Monoclonal antibody | VEGF-A | ||
| Binimetinib | Approved | Small molecule | MEK1/2 | ||
| Brigatinib | Approved | Small molecule | ALK | ||
| Capmatinib | Approved | Small molecule | MET | ||
| Cemiplimab | Approved | Monoclonal antibody | PD-1 | ||
| Ceritinib | Approved | Small molecule | ALK | ||
| Crizotinib | Approved | Small molecule | ALK, ROS1, MET/HGFR, and RON |
…and 53 more. Research shows the complete landscape.
Research
Unlock with Research ↗Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
(63 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
2026 (6)
October 2026 (1)
Phase 2Castration-resistant Prostate Cancer, Metastatic CancerActive not recruiting
Est. primary completion 2026-10-12 · NCT05502315 · CT.gov ↗
What to watch
December 2026 (5)
Phase 1Metastatic Castration-resistant Prostate CancerRecruiting
Est. primary completion 2026-12 · NCT05613894 · CT.gov ↗
What to watch
Phase 2Soft Tissue Sarcoma Adult, Advanced Soft-tissue Sarcoma, Ewing Sarcoma, Osteosarcoma, Undifferentiated Pleomorphic SarcomaRecruiting
Est. primary completion 2026-12 · NCT05182164 · CT.gov ↗
What to watch
Phase 2Metastatic Renal Cell Carcinoma, Clear-cell Metastatic Renal Cell Carcinoma, Neuroendocrine Tumors, Carcinoid TumorRecruiting
Est. primary completion 2026-12 · NCT05263050 · CT.gov ↗
What to watch
Phase 2Papillary Renal Cell Carcinoma, Unclassified Renal Cell Carcinoma, Translocation Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma …Active not recruiting
Est. primary completion 2026-12-20 · NCT04413123 · CT.gov ↗
What to watch
2027 (34)
January 2027 (4)
Phase 1Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-01 · NCT06026410 · CT.gov ↗
What to watch
Phase 2Germ Cell Tumor, Seminoma, Non-seminomatous Germ Cell Tumor, Ovarian Germ Cell TumorActive not recruiting
Est. primary completion 2027-01 · NCT04876456 · CT.gov ↗
What to watch
Phase 2Clinical Stage III Cutaneous Melanoma AJCC v8, Clinical Stage III HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8 …Recruiting
Est. primary completion 2027-01-01 · NCT05136196 · CT.gov ↗
What to watch
Phase 1Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-01-12 · NCT05122546 · CT.gov ↗
What to watch
February 2027 (4)
Phase 1/2Metastatic Renal Cell Carcinoma, Translocation Renal Cell CarcinomaRecruiting
Est. primary completion 2027-02 · NCT06835972 · CT.gov ↗
What to watch
Phase 2Metastatic Soft-tissue SarcomaActive not recruiting
Est. primary completion 2027-02-01 · NCT04551430 · CT.gov ↗
What to watch
Phase 2Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-02-26 · NCT03634540 · CT.gov ↗
What to watch
Phase 2Bladder Adenocarcinoma, Bladder Clear Cell Adenocarcinoma, Bladder Mixed Adenocarcinoma, Bladder Neuroendocrine Carcinoma …Recruiting
Est. primary completion 2027-02-28 · NCT03866382 · CT.gov ↗
What to watch
March 2027 (2)
Phase 2Cancer of KidneyNot yet recruiting
Est. primary completion 2027-03 · NCT05241561 · CT.gov ↗
What to watch
Phase 2Metastatic Lung Non-Squamous Non-Small Cell Carcinoma, Recurrent Lung Non-Squamous Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8Active not recruiting
Est. primary completion 2027-03-31 · NCT04310007 · CT.gov ↗
What to watch
April 2027 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2027-04-07 · NCT07187869 · CT.gov ↗
What to watch
May 2027 (1)
Phase 2Kidney Cancer, Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-05 · NCT04322955 · CT.gov ↗
What to watch
July 2027 (4)
Phase 2Non-Small Cell Lung CancerRecruiting
Est. primary completion 2027-07 · NCT01639508 · CT.gov ↗
What to watch
Phase 2Metastatic Papillary Renal Cell Carcinoma, Stage IV Renal Cell Cancer AJCC v8Active not recruiting
Est. primary completion 2027-07-01 · NCT05411081 · CT.gov ↗
What to watch
Phase 2Anal Melanoma, Bladder Melanoma, Cervical Melanoma, Esophageal Melanoma, Gallbladder Melanoma, Head and Neck Mucosal Melanoma …Active not recruiting
Est. primary completion 2027-07-15 · NCT05111574 · CT.gov ↗
What to watch
Phase 2Malignant Neoplasms of Urinary Tract, Renal Cell Carcinoma, Chromophobe Renal Cell Carcinoma, Metastatic Renal Cell Carcinoma …Active not recruiting
Est. primary completion 2027-07-31 · NCT03541902 · CT.gov ↗
What to watch
August 2027 (3)
Phase 2Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2027-08 · NCT03635892 · CT.gov ↗
What to watch
Phase 1/2Neuroendocrine Tumors,GastroenteropancreaticRecruiting
Est. primary completion 2027-08-31 · NCT05048901 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2027-08-31 · NCT06811116 · CT.gov ↗
What to watch
September 2027 (2)
October 2027 (2)
November 2027 (3)
Phase 1Metastatic Renal Cell Carcinoma, Brain MetastasesActive not recruiting
Est. primary completion 2027-11 · NCT06132945 · CT.gov ↗
What to watch
Phase 1Ewing Sarcoma, Osteosarcoma, SarcomasRecruiting
Est. primary completion 2027-11 · NCT06156410 · CT.gov ↗
What to watch
Phase 1Infiltrating Bladder Urothelial Carcinoma With Squamous Differentiation, Locally Advanced Urothelial Carcinoma …Recruiting
Est. primary completion 2027-11-13 · NCT04878029 · CT.gov ↗
What to watch
December 2027 (8)
Phase 1Neuroendocrine TumorsActive not recruiting
Est. primary completion 2027-12 · NCT05249114 · CT.gov ↗
What to watch
Phase 2Carcinoma, Renal CellRecruiting
Est. primary completion 2027-12 · NCT05127824 · CT.gov ↗
What to watch
Phase 2Locally Advanced Adrenal Cortex Carcinoma, Adrenal Cortical Carcinoma, Stage III Adrenal Cortex Carcinoma …Recruiting
Est. primary completion 2027-12-16 · NCT06006013 · CT.gov ↗
What to watch
Phase 1/2Recurrent Glioblastoma, Recurrent GliosarcomaActive not recruiting
Est. primary completion 2027-12-31 · NCT05039281 · CT.gov ↗
What to watch
Phase 2HCCActive not recruiting
Est. primary completion 2027-12-31 · NCT04588051 · CT.gov ↗
What to watch
Phase 2Locally Advanced Osteosarcoma, Metastatic Osteosarcoma, Recurrent Osteosarcoma, Refractory Osteosarcoma, Unresectable OsteosarcomaRecruiting
Est. primary completion 2027-12-31 · NCT05019703 · CT.gov ↗
What to watch
Phase 2Brain Metastases, Renal Cell CarcinomaRecruiting
Est. primary completion 2027-12-31 · NCT05048212 · CT.gov ↗
What to watch
Phase 4Thyroid NeoplasmsNot yet recruiting
Est. primary completion 2027-12-31 · NCT07010393 · CT.gov ↗
What to watch
2028 (10)
January 2028 (1)
Phase 3Clear Cell Renal Cell CarcinomaActive not recruiting
Est. primary completion 2028-01-25 · NCT03793166 · CT.gov ↗
What to watch
March 2028 (1)
Phase 1Autoimmune Disease, Crohn Disease, Dermatomyositis, Hematopoietic and Lymphoid Cell Neoplasm, Inflammatory Bowel Disease …Recruiting
Est. primary completion 2028-03-30 · NCT03816345 · CT.gov ↗
What to watch
April 2028 (2)
June 2028 (3)
Phase 2Hepatocellular CarcinomaNot yet recruiting
Est. primary completion 2028-06 · NCT07151326 · CT.gov ↗
What to watch
Phase 2Metastatic Renal Cell Carcinoma, Stage III Renal Cell Cancer AJCC v8, Stage IV Renal Cell Cancer AJCC v8, Unresectable Renal Cell CarcinomaRecruiting
Est. primary completion 2028-06-15 · NCT05327686 · CT.gov ↗
What to watch
Phase 1/2Hepatocellular CarcinomaRecruiting
Est. primary completion 2028-06-30 · NCT03539822 · CT.gov ↗
What to watch
July 2028 (1)
Phase 3CancerActive not recruiting
Est. primary completion 2028-07-05 · NCT03768063 · CT.gov ↗
What to watch
September 2028 (1)
Phase 2Metastatic Squamous Non-Small Cell Lung CarcinomaRecruiting
Est. primary completion 2028-09 · NCT05613413 · CT.gov ↗
What to watch
October 2028 (1)
Phase 4Renal Cell Carcinoma (Kidney Cancer), Metastatic Renal Cell Carcinoma, Locally AdvancedRecruiting
Est. primary completion 2028-10 · NCT07028125 · CT.gov ↗
What to watch
2029 (5)
March 2029 (1)
Phase 1Clear Cell Renal Cell CarcinomaRecruiting
Est. primary completion 2029-03 · NCT05536141 · CT.gov ↗
What to watch
June 2029 (1)
Phase 2Locally Advanced Adrenal Cortical Carcinoma, Metastatic Adrenal Cortical Carcinoma, Recurrent Adrenal Cortical Carcinoma …Recruiting
Est. primary completion 2029-06-02 · NCT06900595 · CT.gov ↗
What to watch
July 2029 (1)
Phase 3Advanced Bladder Urothelial Carcinoma, Advanced Renal Pelvis Urothelial Carcinoma, Advanced Ureter Urothelial Carcinoma …Active not recruiting
Est. primary completion 2029-07-15 · NCT05092958 · CT.gov ↗
What to watch
August 2029 (1)
November 2029 (1)
Phase 1/2Advanced Renal Cell Carcinoma (RCC)Recruiting
Est. primary completion 2029-11-28 · NCT07293351 · CT.gov ↗
What to watch
2030 (4)
May 2030 (1)
Phase 3Clear Cell Renal Cell CarcinomaEnrolling by invitation
Est. primary completion 2030-05-31 · NCT07620574 · CT.gov ↗
What to watch
September 2030 (2)
Phase 3Renal Cell Carcinoma (Kidney Cancer), Kidney Cancer Metastatic, Renal Cell Carcinoma MetastaticRecruiting
Est. primary completion 2030-09-30 · NCT06726421 · CT.gov ↗
What to watch
Phase 3Refractory Differentiated Thyroid Gland CarcinomaRecruiting
Est. primary completion 2030-09-30 · NCT06475989 · CT.gov ↗
What to watch
October 2030 (1)
Phase 1Metastatic Ewing SarcomaRecruiting
Est. primary completion 2030-10 · NCT07194044 · CT.gov ↗
What to watch
2032 (1)
May 2032 (1)
Phase 3Metastatic Kidney Cancer, Metastatic Kidney CarcinomaRecruiting
Est. primary completion 2032-05-05 · NCT06364631 · CT.gov ↗
What to watch
2033 (2)
2034 (1)
April 2034 (1)
Phase 3Von Hippel-Lindau Disease, Malignant NeoplasmsRecruiting
Est. primary completion 2034-04-22 · NCT07405164 · CT.gov ↗
What to watch
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.